A carregar...
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective
Checkpoint inhibitors targeting the programmed cell death 1 protein (PD-1) and programmed cell death ligand 1 (PD-L1) are demonstrating promising efficacy and appear to be well tolerated in a number of tumour types. In non-small-cell lung cancer, head-and-neck squamous cell carcinoma, and urothelial...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6023555/ https://ncbi.nlm.nih.gov/pubmed/29962847 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.4031 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|